Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Cullinan Management ( (CGEM) ) has shared an announcement.
On November 3, 2025, Cullinan Therapeutics announced promising new clinical data from its Phase 1 study of CLN-049, a novel FLT3xCD3 T cell engager, in patients with relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The data, to be presented at the 67th American Society of Hematology Annual Meeting in December, showed significant anti-leukemic activity and a manageable safety profile, with a composite complete response rate of 31% at the highest dose level. These findings highlight CLN-049’s potential as a new treatment option for AML, a disease with limited current therapies, especially for patients with high-risk genetic features.
The most recent analyst rating on (CGEM) stock is a Buy with a $34.00 price target. To see the full list of analyst forecasts on Cullinan Management stock, see the CGEM Stock Forecast page.
Spark’s Take on CGEM Stock
According to Spark, TipRanks’ AI Analyst, CGEM is a Underperform.
Cullinan Management’s stock is facing significant challenges primarily due to its weak financial performance, characterized by persistent losses and negative cash flow. The technical analysis provides some short-term optimism, but the overall technical outlook remains bearish. The valuation is unattractive due to a negative P/E ratio and no dividend yield, indicating high risk for investors. The stock’s potential is heavily reliant on strategic changes and improved financial health.
To see Spark’s full report on CGEM stock, click here.
More about Cullinan Management
Cullinan Therapeutics, Inc. is a biopharmaceutical company focused on developing potential first- or best-in-class therapies for autoimmune diseases and cancer. The company leverages expertise in T cell engagers, with a clinical-stage pipeline aimed at delivering new standards of care.
Average Trading Volume: 868,153
Technical Sentiment Signal: Hold
Current Market Cap: $511.6M
For detailed information about CGEM stock, go to TipRanks’ Stock Analysis page.